Evidence map›Paper›PMID 40873218›Full record

ReviewCurrent drug metabolism2025

Advances in Controlled Release Formulations for Ocular Diseases: Improving Patient Compliance and Therapeutic Outcomes.

Smita Narwal, Dushyant, Gurvirender Singh, Nisha Grewal, Vishal Chanalia, Ashwani K Dhingra

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current drug metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Smita NarwalDepartment of Pharmacy, Global Research Institute of Pharmacy, Radaur, Yamunanagar-135133, Haryana, India.ORCID 0009-0000-6506-9234
DushyantDepartment of Pharmacy, Global Research Institute of Pharmacy, Radaur, Yamunanagar-135133, Haryana, India.
Gurvirender SinghDepartment of Pharmaceutical Sciences, Institute of Pharmaceutical Sciences, Kurukshetra University, Kurukshetra-136119, Haryana, India.ORCID 0009-0003-7938-1546
Nisha GrewalDepartment of Pharmacy, Global Research Institute of Pharmacy, Radaur, Yamunanagar-135133, Haryana, India.ORCID 0009-0000-9139-0718
Vishal ChanaliaDepartment of Pharmacy, Global Research Institute of Pharmacy, Radaur, Yamunanagar-135133, Haryana, India.
Ashwani K DhingraDepartment of Pharmacy, Global Research Institute of Pharmacy, Radaur, Yamunanagar-135133, Haryana, India.ORCID 0000-0001-7574-2971

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A majority of the global population suffers from eye diseases, but few effective treatment options are available with ophthalmic drug therapies. The reasons that have been identified are (1) lack of awareness about the options for treatments, drugs, polymeric science, or physiological barriers, (2) limitations in bringing drug therapies to the posterior segment of the eye due to physiological or anatomical limitations, and (3) regulatory and production difficulties of ocular drug products. Innovative ocular medication delivery and therapies are covered in this study, including hydrogels, nano micelles, implants, nanoparticles, microparticles, liposomes,

Indexed as

Delayed-Action PreparationsEye DiseasesAdministration, OphthalmicAnimalsDrug Delivery SystemsHumansPatient ComplianceDelayed-Action Preparationsbioavailability enhancementnanotechnologyocular diseasesOcular drug deliveryophthalmic drug.physiological barriers

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.